Valeant is getting beat up again

Pharmaceutical firm Valeant’s stock continued its sell off Monday morning with the stock opening down over 5%.

The stock started falling on September 18, when lawmakers started taking action against companies that gouge the prices of prescription drugs. Since then, it’s lost a quarter of its value.

Washington’s interest was peaked when the world found out about Martin Shkreli, a hedge fund manager who purchased a prescription drug and jacked up the price 5,000%.

That started a conversation about pharmaceutical firms that engage in the same behaviour, and Valeant — a Wall Street darling with a connection to hedge fund manager Bill Ackman — was pinpointed as one of the worst offenders.

Last week, short selling firm Citron research released a note about Valeant with a table listing all the drugs the company purchased and their price increases:

NOW WATCH: We got our hands on Donald Trump’s failed 1989 board game and it’s bizarre

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at